- Home
- HQH vs ORIC Comparison
HQH vs ORIC Comparison
Compare HQH & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQH | ORIC |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | 111 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HQH | ORIC |
|---|---|---|
| Price | $21.25 | $13.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 120.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.14 | $7.23 |
| 52 Week High | $24.85 | $14.93 |
Technical Indicators
Market Signals| Indicator | HQH | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 56.03 |
| Support Level | $18.73 | $13.12 |
| Resistance Level | $22.29 | $14.27 |
| Average True Range (ATR) | 0.41 | 0.69 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 9.87 | 68.69 |
Price Performance
Historical ComparisonAbout HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.